All In Biotech

Drug Trial Radar · NCT06525389

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

428

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 1, 2030

Study completion Sep 1, 2031

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Pham Ngoc Thach University of Medicine; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; National Hospital for Tropical Diseases, Hanoi, Vietnam; Bach Mai Hospital; Gilead Sciences; Viatris Inc.
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions: 1. Is induction therapy using a single 10 mg\\/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)? 2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone? 3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

Conditions

  • Talaromycosis

Interventions

  • Liposomal Amphotericin B (LAmB)Drug

    Antifungal dosed at 10 mg/kg/day IV x one single dose.

  • Flucytosine (5FC)Drug

    Antifungal dosed at 25mg/kg oral 3x daily.

  • Flucytosine (5FC) placebo pillDrug

    Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.

  • Deoxycholate Amphotericin B (DAmB)Drug

    Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from enrollment to a composite of poor outcomesTime frame: up to 24 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

  • Bach Mai Hospital

    Hanoi, Vietnam

  • National Hospital for Tropical Diseases

    Hanoi, Vietnam

  • Hospital for Tropical Diseases

    Ho Chi Minh City, Vietnam

  • Pham Ngoc Thach University of Medicine

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.